Capital Advantage’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Advantage’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-5,351	Closed	-$288K	–	70
2014 Q3	$288K	Hold	5,351	–	–	0.15%	42
2014 Q2	$280K	Hold	5,351	–	–	0.15%	40
2014 Q1	$283K	Hold	5,351	–	–	0.2%	34
2013 Q4	$214K	Buy	+5,351	New	+$211K	0.14%	41

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Advantage's TEVA Position: Q4 2014 in Review

Capital Advantage sold out of Teva Pharmaceuticals (TEVA) in Q4 2014, closing a stake of 5,351 shares — an estimated $288K sold.

Capital Advantage first reported a position in TEVA in Q4 2013 and held it in 4 quarters. The position peaked at $288K in Q3 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

Capital Advantage reported no remaining Teva Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Capital Advantage sold 5,351 Teva Pharmaceuticals shares in Q4 2014, an estimated $288K.
Capital Advantage first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 4 quarters.
Capital Advantage's Teva Pharmaceuticals position peaked at $288K in Q3 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Capital Advantage's 13F filing for Q4 2014, filed 15 May 2015.